Saturday, May 28th, 2022
- Plenary session 4: Hemostatic complications and novel anti-cancer therapies
Chairs: I. Weitz (USA), W. Ruf (Germany)
PL-13 - Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy
K. McCrae (USA)
PL-14 - Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer treatments
F. Moik (Austria)
PL-15 - Drug-drug interactions: Implications for anticoagulation use in patients with cancer
T.F. Wang (Canada)
PL-16 - Bleeding risk with direct oral anticoagulants in cancer patients
R. Bauersachs (Germany)
Selected Abstract
- Plenary session 5: COVID-19, thrombosis, and cancer
Chairs: H.A. Liebman (Italy), V. De Stefano (Italy)
PL-17 - Cancer and COVID-19: where are the data?
N. Kuderer (USA)
PL-18 - COVID-19 associated coagulopathy and thrombosis in cancer
M.M. Levi (UK)
PL-19 - COVID-19 impact on thrombosis in hematological malignancies
M.N. Lauw (The Netherlands)
PL-20 - Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer
J.M. Connors (USA)
Selected Abstract
- Poster Sessions
- Roundtable: Multidisciplinary approach in Cardiovascular Oncology
Chairs: I. Pabinger (Austria), A. ten Cate-Hoek (NL)
Introduction: Building a CAT Clinic - Real-World Systems Approaches to Prevention and Treatment
A.A. Khorana (USA)
Discussants: B. Brenner (Israel), A.J. Kakkar (UK), I. Elalamy (France), A.J. Munoz (Spain), M.B. Monreal (Spain), N. Van Es (The Netherlands)